Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories is currently trading at Rs. 2666.70, up by 38.60 points or 1.47% from its previous closing of Rs. 2628.10 on the BSE.

The scrip opened at Rs. 2678.00 and has touched a high and low of Rs. 2681.00 and Rs. 2661.15 respectively. So far 7,141 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2382.05 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 2681.00 and Rs. 2548.15 respectively. The current market cap of the company is Rs. 44,169.00 crore.

The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 42.95% and 13.87% respectively.

Dr. Reddy’s Laboratories has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) as closure of audit for Miryalaguda facility. Miryalaguda plant supplies active ingredients for company’s captive consumption as well as for its customers.

Earlier in February, the USFDA had conducted an audit of API manufacturing plant at Miryalaguda, wherein the company was issued a form 483 with three observations for the said facility.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.